Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -1.61% 610.00 610.00 616.00 628.00 614.00 628.00 33,967 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 233

International Biotechnol... Share Discussion Threads

Showing 201 to 221 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
01/6/2012
15:39
NAV Thursday 31 May Ex Income 221.32
davebowler
09/5/2012
14:55
NAV Tuesday 08 May Excluding Income 216.05
davebowler
27/4/2012
09:27
Portfolio Update The Board of International Biotechnology Trust plc (the "Company") notes that today a definitive agreement has been signed by Jazz Pharmaceuticals (NASDAQ:JAZZ) to buy the unquoted portfolio company EUSA Pharma for $650m in cash plus a potential $50m milestones payment. The Director's have changed the valuation of the Company's interest in EUSA Pharma by £1.9m from £2.7m to £4.6m on a cost of £2.4m to reflect the terms of the deal. This change in valuation will be included in the Company's Net Asset Value from today and will be released to the market on Monday. The increase to NAV per share in comparison to that released yesterday is 3.5 pence per share. Enquiries: Kate Bingham/David Pinniger Telephone: 020 7412 7070
davebowler
16/4/2012
10:47
Edison view; International Biotechnology Trust - Quoted portfolio continues to outperform PDF download Click for report International Biotechnology Trust's (IBT) quoted portfolio has, for the past three years, outperformed the NASDAQ Biotechnology Index. Although the unquoted portfolio (c 16%) has been a drag on overall performance, it is reaching maturity and may provide uplifts on exit, as reflected in the 2011 sale of Cadent to Align Technologies at 3.1x the carrying book value. The manager reports that exit conditions have improved significantly during the past six months, and currently expects five to six actions per year for the next two years, with further events in 2014/15. IBT aims to achieve long-term capital growth by investing in development stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential. IBT invests in companies considered to have good prospects, experienced management and strong upside potential through the development and/or commercialisation of a product, device or enablin g technology.
davebowler
09/2/2012
18:44
Steadily South.
sharejock
06/2/2012
15:51
Steadily North.
sharejock
06/12/2011
18:34
Tomorrow`s AGM should be interesting. The share buyback / cancellation process is very active.
gilston
06/12/2011
15:58
Amazing really - this is at an all time high.
davebowler
05/12/2011
16:45
Improving!
gilston
25/10/2011
12:25
Edison; International Biotechnology Trust - Improved fee structure PDF download Click for report With the recent results announcement, International Biotechnology Trust (IBT) confirmed a reduction in the annual management fee by 20bps to 1.15% of NAV with the aim of reducing the overall TER to below 2.0%. The quoted portfolio performance fee is also being adjusted, to 10% of any outperformance above the NASDAQ (sterling adjusted) Biotechnology Index plus 0.5%. The maximum total performance fee payable in a year falls from 5% of NAV to 3%. For now, the unquoted portfolio continues to act as a break on overall performance. However, IBT has recently successful exited Cadent with a sale to Align Technologies, at 3.1x book value. While recent market conditions have arguably delayed further exits the manager, SV Life Sciences, believes many of the unquoted names are reaching maturity and will provide strong exits, which will give a significant uplift to the unquoted performance. IBT aims to achieve long-term capital growth by investing in deve lopment stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential.
davebowler
17/10/2011
14:45
Date NAV Pence Friday 14(th) October Excluding Income 174.08
davebowler
19/9/2011
08:55
Thursday 15 September NAV Excluding Income 172.77
davebowler
09/9/2011
11:26
NAV Thursday 08 September 170.52
davebowler
05/9/2011
12:56
NAV Friday 02 September Excluding Income 164.25
davebowler
21/6/2011
08:51
http://www.investmentweek.co.uk/investment-week/analysis/2075951/medical-innovation-brings-health-biotech-sector
davebowler
19/5/2011
12:23
18 May 2011 International Biotechnology Trust plc The Board of International Biotechnology Trust plc announces that the unaudited net asset value per share Date NAV Pence Tuesday 17 May Excluding Income 183.34
davebowler
19/5/2011
12:23
http://www.moneyweek.com/news-and-charts/people-in-the-news/guru-watch/drug-stocks-pharmaceuticals-neil-woodford-10713
davebowler
26/4/2011
12:58
Wednesday 20 April NAV 179.01
davebowler
14/4/2011
09:10
Tuesday 12 April NAV 177.3
davebowler
11/4/2011
12:51
Friday 08 April NAV Excluding Income 176.90
davebowler
31/12/2010
16:21
Thursday 30 December NAV Excluding Income 181.09
davebowler
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200125 05:39:16